drugset / Trial / NCT01420510

Saginil in vs. Placebo for Gynecologic Oncology Patients Affected by Vaginitis

NCT01420510 ↗

Phase 2/3 Unknown 60 enrolled University of Insubria
RandomizedParallel-groupQuadruple-blindPrevention

Summary

We hypothesise that the use of Adelmidrol (Saginil in vaginal cannulas) can reduce the incidence and magnitude of vaginitis in patients affected by gynecologic malignancies.

Timeline

Start
2011-09
Primary completion
2014-11
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Adelmidrol Small molecule — Other

Indications